2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06B.03 Performance of a Prognostic OTP, CD44, Ki-67 Biomarker Panel for Relapse in Paired Biopsies and Resections of Pulmonary Carcinoids

EP.06B.03 Performance of a Prognostic OTP, CD44, Ki-67 Biomarker Panel for Relapse in Paired Biopsies and Resections of Pulmonary Carcinoids

Back to course

Pdf Summary

The study conducted by Tijmen van Weert at Maastricht University Medical Centre evaluates a prognostic biomarker panel comprising OTP, CD44, and Ki-67 for predicting relapse in patients with pulmonary carcinoids (PC), particularly in paired biopsies and resections. Pulmonary carcinoids, comprising typical (low grade) and atypical (intermediate grade) types, have varying relapse rates and survival outcomes. The typical carcinoid (TC) has a lower relapse rate (3-6%), while atypical carcinoid (AC) sees higher relapse (20-35%).<br /><br />The panel aims to enhance the stratification of patients at risk for relapse, potentially refining treatment plans and follow-up protocols, thus improving patient outcomes and quality of life. Initial biomarkers were validated on resection specimens, but this study investigates their utility on biopsy material, which might allow pre-operative identification of high-risk patients.<br /><br />The retrospective study assessed paired biopsy-resection samples from the Netherlands Pathology and Cancer registries, focusing on cases with complete staining of the biomarkers. Out of 92 cases, relapse was observed in 12. Two pathologists evaluated the biomarker expressions, establishing cut-off values for stratification into low or high relapse risk groups.<br /><br />Results indicated that the biomarker panel, compared to the WHO 2021 classification, significantly improved the predictive accuracy of relapse in PC patients based on biopsies. The panel showed a substantial agreement among pathologists, reflecting better diagnostic concordance. Significant correlations were observed, particularly for OTP and CD44 between biopsy and resection specimens, suggesting the panel's reliability in biopsies.<br /><br />In conclusion, the biomarker panel enhances the identification of PC patients likely to relapse, suggesting a shift towards personalized treatment strategies. This approach could inform clinicians and enable more tailored interventions, optimizing treatment decisions and reducing unnecessary interventions for low-risk patients.

Asset Subtitle

Jules Derks

Meta Tag

Speaker Jules Derks

Topic Pathology and Biomarkers

Keywords

prognostic biomarker panel

OTP

CD44

Ki-67

pulmonary carcinoids

relapse prediction

biopsies

personalized treatment

patient stratification

diagnostic concordance